Novo Nordisk A Slash S

Novo Nordisk A/S, a Danish pharmaceutical preparation manufacturer, reported total emissions of approximately 2.69 billion kg CO2e in 2025. This includes about 120 million kg CO2e from Scope 1 emissions, approximately 63 million kg CO2e from Scope 2 market-based emissions, and roughly 2.51 billion kg CO2e from Scope 3 emissions.

For 2024, the company's total emissions were approximately 2.26 billion kg CO2e, with around 85 million kg CO2e from Scope 1, about 16 million kg CO2e from Scope 2 market-based emissions, and roughly 2.16 billion kg CO2e from Scope 3 emissions. In 2023, Novo Nordisk A/S's total emissions stood at approximately 1.84 billion kg CO2e, comprising about 78 million kg CO2e from Scope 1, roughly 15 million kg CO2e from Scope 2 market-based emissions, and around 1.74 billion kg CO2e from Scope 3 emissions.

Novo Nordisk A/S has set ambitious climate commitments, validated by the Science Based Targets initiative (SBTi). The company is committed to achieving net-zero greenhouse gas emissions across its entire value chain by 2045. As part of its near-term targets, Novo Nordisk A/S aims to reduce absolute Scope 1 and 2 GHG emissions by 100% by 2030, using a 2024 base year. Additionally, the company commits to a 33% absolute reduction in Scope 3 GHG emissions by 2033, also from a 2024 base year, specifically targeting emissions from purchased goods and services, capital goods, upstream and downstream transportation and distribution, and business travel. Long-term targets include maintaining a minimum of 100% absolute Scope 1 and 2 GHG emissions reduction from 2030 through 2045, and a 90% absolute Scope 3 GHG emissions reduction by 2045, both from a 2024 base year.